For example, halofuginone and pirfenidone, known antifibrotic agents, have shown promise in modulating collagen matrix architecture in various cancer models, including PDAC, while Losartan, an FDA-approved anti-hypertensive drug, has demonstrated antifibrotic effects by suppressing active TGF-β1 levels [44, 47]. The gene discussed is TGFB1; the disease is cancer.